JP2010528995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528995A5 JP2010528995A5 JP2010509701A JP2010509701A JP2010528995A5 JP 2010528995 A5 JP2010528995 A5 JP 2010528995A5 JP 2010509701 A JP2010509701 A JP 2010509701A JP 2010509701 A JP2010509701 A JP 2010509701A JP 2010528995 A5 JP2010528995 A5 JP 2010528995A5
- Authority
- JP
- Japan
- Prior art keywords
- alk
- het
- proportions
- atoms
- pharmaceutically usable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- -1 1-azabicyclo [2.2.2] octanyl Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims 1
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007025718.1 | 2007-06-01 | ||
| DE102007025718A DE102007025718A1 (de) | 2007-06-01 | 2007-06-01 | Pyridazinonderivate |
| PCT/EP2008/003550 WO2008145243A1 (de) | 2007-06-01 | 2008-05-02 | Pyridazinonderivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010528995A JP2010528995A (ja) | 2010-08-26 |
| JP2010528995A5 true JP2010528995A5 (enExample) | 2011-06-23 |
| JP5485875B2 JP5485875B2 (ja) | 2014-05-07 |
Family
ID=39671665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509701A Expired - Fee Related JP5485875B2 (ja) | 2007-06-01 | 2008-05-02 | ピリダジノン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8367668B2 (enExample) |
| EP (1) | EP2150539B1 (enExample) |
| JP (1) | JP5485875B2 (enExample) |
| KR (1) | KR20100027188A (enExample) |
| CN (1) | CN101679303B (enExample) |
| AR (1) | AR066770A1 (enExample) |
| AU (1) | AU2008255328B2 (enExample) |
| BR (1) | BRPI0812247A2 (enExample) |
| CA (1) | CA2688518C (enExample) |
| DE (1) | DE102007025718A1 (enExample) |
| EA (1) | EA200901601A1 (enExample) |
| ES (1) | ES2444218T3 (enExample) |
| IL (1) | IL202376A (enExample) |
| MX (1) | MX2009012708A (enExample) |
| WO (1) | WO2008145243A1 (enExample) |
| ZA (1) | ZA200909054B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008062826A1 (de) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| CN102458122A (zh) * | 2009-04-20 | 2012-05-16 | 人类健康研究所 | 含有哒嗪磺胺衍生物的化合物、组合物和方法 |
| EP2515657A4 (en) * | 2009-12-21 | 2013-07-03 | Merck Sharp & Dohme | Tyrosine kinase inhibitor |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| CN102731409A (zh) * | 2011-04-08 | 2012-10-17 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物，其药物组合物、制备方法及用途 |
| EP2858982A4 (en) | 2012-06-12 | 2015-11-11 | Abbvie Inc | PYRIDINONE AND PYRIDAZINONE DERIVATIVES |
| EP2888256A4 (en) * | 2012-08-24 | 2016-02-17 | Univ Texas | HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES |
| ES2691643T3 (es) | 2012-08-24 | 2018-11-28 | Board Of Regents, The University Of Texas System | Moduladores heterocíclicos de la actividad de HIF para el tratamiento de enfermedades |
| CN103664895B (zh) * | 2012-08-28 | 2018-02-27 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及其用途 |
| EA035727B1 (ru) * | 2013-10-18 | 2020-07-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы бромодомена |
| KR102116107B1 (ko) | 2013-12-30 | 2020-05-28 | 삼성디스플레이 주식회사 | 표시 장치 |
| US9988421B2 (en) | 2014-01-10 | 2018-06-05 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
| DK3110420T3 (da) | 2014-02-25 | 2019-05-13 | Board Of Regents Univ Of Texas System | Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme |
| US11202817B2 (en) | 2014-08-18 | 2021-12-21 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| KR102764027B1 (ko) | 2015-10-15 | 2025-02-07 | 코넬 유니버시티 | 프로테아좀 억제제 및 이의 용도 |
| KR20180084478A (ko) | 2017-01-17 | 2018-07-25 | 김민규 | 파일 인양을 위한 굴절케이싱 및 이를 이용한 파일 인양방법 |
| US11203613B2 (en) | 2017-10-11 | 2021-12-21 | Cornell University | Peptidomimetic proteasome inhibitors |
| EP3877376B1 (en) | 2018-11-06 | 2023-08-23 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| AU2019374812B2 (en) * | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CA3118908A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN114105976B (zh) * | 2020-08-28 | 2024-04-26 | 杭州邦顺制药有限公司 | 选择性rock2激酶抑制剂 |
| JP2024540485A (ja) * | 2021-11-17 | 2024-10-31 | エッジワイズ セラピューティクス， インコーポレイテッド | ピリダジノン化合物およびその使用 |
| CA3247018A1 (en) * | 2022-02-03 | 2023-08-10 | De Shaw Res Llc | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO79566A2 (ro) * | 1980-05-28 | 1982-08-17 | Institutul De Cercetari Chimico-Farmaceutice,Ro | Substante din clasa 2-(3'-aril-piridazonil-1'5-metil-5-aril-(alchil)amino-tiadiazolului |
| RO79562A2 (ro) * | 1980-05-29 | 1982-08-17 | Institutul De Cercetari Chimico-Farmaceutice,Ro | Substante din clasa 3-(3'-aril-piridazonil-1'5-metil-4-aril(alchil)-5-mercapto-1,2,4-triazolului si procedeu de obtinere a acestora |
| JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| JPS5826802A (ja) * | 1981-08-10 | 1983-02-17 | Sankyo Co Ltd | 農園芸用殺菌剤 |
| DE4134467A1 (de) * | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| ATE180475T1 (de) * | 1990-09-21 | 1999-06-15 | Rohm & Haas | Dihydropyridazinone und pyridazinone als fungizide |
| IL115889A0 (en) | 1994-11-14 | 1996-01-31 | Rohm & Haas | Pyridazinones and their use as fungicides |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | ４―アニリノキナゾリン誘導体 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| DE69833774T2 (de) * | 1997-08-22 | 2007-04-26 | Abbott Laboratories, Abbott Park | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren |
| KR100626605B1 (ko) | 1997-11-19 | 2006-09-22 | 코와 가부시키가이샤 | 신규 피리다진 유도체 및 이를 유효성분으로 하는 의약 |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| CA2410562A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| AUPR606401A0 (en) * | 2001-07-02 | 2001-07-26 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| EP1463509A1 (en) * | 2001-10-31 | 2004-10-06 | MERCK PATENT GmbH | Type 4 phosphodiesterase inhibitors and uses thereof |
| EP1470112A1 (en) * | 2002-01-18 | 2004-10-27 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
| WO2006095666A1 (ja) * | 2005-03-07 | 2006-09-14 | Kyorin Pharmaceutical Co., Ltd. | ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| DE102005055354A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine |
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| EP2114898A2 (en) * | 2007-02-16 | 2009-11-11 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
-
2007
- 2007-06-01 DE DE102007025718A patent/DE102007025718A1/de not_active Withdrawn
-
2008
- 2008-05-02 ES ES08758367.0T patent/ES2444218T3/es active Active
- 2008-05-02 EP EP08758367.0A patent/EP2150539B1/de not_active Not-in-force
- 2008-05-02 CN CN2008800179692A patent/CN101679303B/zh not_active Expired - Fee Related
- 2008-05-02 CA CA2688518A patent/CA2688518C/en active Active
- 2008-05-02 KR KR1020097027591A patent/KR20100027188A/ko not_active Withdrawn
- 2008-05-02 BR BRPI0812247-4A patent/BRPI0812247A2/pt not_active IP Right Cessation
- 2008-05-02 WO PCT/EP2008/003550 patent/WO2008145243A1/de not_active Ceased
- 2008-05-02 EA EA200901601A patent/EA200901601A1/ru unknown
- 2008-05-02 JP JP2010509701A patent/JP5485875B2/ja not_active Expired - Fee Related
- 2008-05-02 AU AU2008255328A patent/AU2008255328B2/en not_active Ceased
- 2008-05-02 MX MX2009012708A patent/MX2009012708A/es not_active Application Discontinuation
- 2008-05-02 US US12/602,254 patent/US8367668B2/en not_active Expired - Fee Related
- 2008-05-30 AR ARP080102271A patent/AR066770A1/es unknown
-
2009
- 2009-11-26 IL IL202376A patent/IL202376A/en active IP Right Grant
- 2009-12-18 ZA ZA200909054A patent/ZA200909054B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528995A5 (enExample) | ||
| JP2010532768A5 (enExample) | ||
| JP2011530545A5 (enExample) | ||
| HRP20120661T1 (hr) | Derivati pirimidinil piridazinona | |
| JP2015515961A5 (enExample) | ||
| JP2010529051A5 (enExample) | ||
| JP2020097596A5 (enExample) | ||
| CA2878251A1 (en) | Method of treating gastrointestinal stromal tumors | |
| JP2011510055A5 (enExample) | ||
| JP2011518202A5 (enExample) | ||
| JP5788527B2 (ja) | キナーゼ阻害剤の副作用低減剤 | |
| JP2014501732A (ja) | 骨癌の疼痛におけるシグマリガンドの使用 | |
| WO2012144463A1 (ja) | 腫瘍治療剤 | |
| JP2015529194A5 (enExample) | ||
| AU2015360006B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative | |
| JP2009534418A5 (enExample) | ||
| JP2010519278A5 (enExample) | ||
| WO2022005871A1 (en) | Methods of treating sars-cov-2 infection using inhibitors of lipogenesis | |
| BR112020025670A2 (pt) | Alcóxi pirazóis como ativadores de guanilato ciclase solúveis | |
| US20120213867A1 (en) | Raf inhibitors for the treatment of thyroid cancer | |
| ES2824400T3 (es) | Agente antitumoral que incluye clorhidrato de irinotecán hidratado | |
| AU2013339823B2 (en) | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (HCC) | |
| ES2679372T3 (es) | Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad contra el cáncer con un inhibidor de MEK | |
| CA2970391A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor | |
| JP7130180B2 (ja) | 子宮内膜症の処置のためのインドールの新規誘導体 |